A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
Status:
Recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, open label study to investigate the safety and efficacy
of Gentuximab plus Almonertinib in metastatic NSCLC patients with EGFR mutation-positive.